氨基己酸临床用药的研究现状  

Research status on the clinical application of aminocaproicacid

作　　者：罗序睿[1] 黄亮[1] LUO Xu-rui;HUANG Liang(Department of Emergency,The First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China)

机构地区：[1]南昌大学第一附属医院急诊科,江西南昌330006

出　　处：《中国临床药理学杂志》2022年第16期1967-1971,1976,共6页The Chinese Journal of Clinical Pharmacology

摘　　要：氨基己酸抑制纤维蛋白溶解酶原的激活因子,使纤维蛋白溶酶原不能转变为纤维蛋白溶酶,进而抑制蛋白的溶解,适用于防治纤维蛋白溶解亢进引起的出血。氨基己酸在临床上已广泛应用于骨科、胸外、脑外等手术术中和术后出血的防控和纤溶亢进性疾病。本文基于氨基己酸在相关出血凝血纤溶障碍性疾病中的临床研究相关证据,对相关指南和文献报道的适应症予以综述和评价,以期为临床上合理使用氨基己酸提供借鉴。Aminocaproic acid inhibits the activator of fibrinolytic enzyme and prevents the conversion of fibrinolytic enzyme into fibrinolytic enzyme,thus inhibiting the dissolution of protein,which is crucial for the prevention and treatment of bleeding caused by hyperfibrinolytic disease.Clinically,it is not only widely used in the prevention and control of bleeding during and after surgery in orthopedics,chest and brain operations,but also often applied in emergency departments and hematology departments to deal with hypervolutriosis diseases.Based on the evidence of clinical studies of caproic acid in various bleeding and coagulation disorders,we reviewed and evaluated the relevant guidelines and clinical reports in order to provide reference for rational use of caproic acid.

关 键 词：氨基己酸 纤维蛋白溶酶原 纤维蛋白溶解亢进 出血 止血 

分 类 号：R973.2[医药卫生—药品]